CHMP scolds AB Science (again) for masitinib shortcomings, triggering a new rout on stock price

0

Less than a year ago French regulators ordered a trial halt on masitinib to make sure the biotech was operating in accordance with the rules on trial conduct. AB Science said at the time that the ANSM zeroed in on a troubled study —AB06006 — involving masitinib in treating mastocytosis. But those …

Source: CHMP scolds AB Science (again) for masitinib shortcomings, triggering a new rout on stock price

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Subscribe To Inside Alpha

Take the first step toward gaining exclusive access & insight into the world’s wealthiest, savviest most successful investors:

Subscribe to Inside Alpha now – it could change your life forever & it’s FREE!

You're in! Check your inbox shortly for more details.